Aiolos Is Required for the Generation of High Affinity Bone Marrow Plasma Cells Responsible for Long-Term Immunity
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Antigenic encounter generates long-term immunity sustained by long-lived high affinity plasma cells resident in the bone marrow (BM). Here we show that the Ikaros family member, Aiolos, is specifically required for the generation of these plasma cells. Failure to generate high affinity plasma cells in the BM and to sustain serum antibody titers is apparent after both primary and secondary immunization of Aiolos−/− mice with a range of hapten concentrations. Chimera reconstitutions demonstrate that the BM plasma cell defect is B cell intrinsic. Lack of Aiolos does not alter expression of any of the previously described factors required for general plasma cell differentiation. No defect in somatic hypermutation, the generation of memory B cells, or short-lived high affinity plasma cells in the spleen was observed upon rechallenge. These studies support a model by which the high affinity plasma cell population in the BM undergoes a unique differentiation program that is dependent on Aiolos.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ikaros DNA-Binding Proteins Direct Formation of Chromatin Remodeling Complexes in Lymphocytes
Kim, J., Sif, S., Jones, B., Jackson, A., Koipally, J., Heller, E., Winandy, S., Viel, A., Sawyer, A., Ikeda, T., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80034-5 · Cited by 587
Self-citationMorgan, B., Sun, L., Avitahl, N., Andrikopoulos, K., Ikeda, T., Gonzales, E., Wu, P., Neben, S., & Georgopoulos, K. (1997) · The EMBO Journal · doi:10.1093/emboj/16.8.2004 · Cited by 367 · cited 2×
“Unlike Ikaros, Aiolos deficiency does not affect early B cell differentiation in the BM, consistent with its absence or low expression relative to Ikaros at these early developmental stages (11, 12).”
BackgroundSelf-citationAiolos Regulates B Cell Activation and Maturation to Effector State
Wang, J.-H., Avitahl, N., Cariappa, A., Friedrich, C., Ikeda, T., Renold, A., Andrikopoulos, K., Liang, L., Pillai, S., Morgan, B. A., et al. (1998) · Immunity · doi:10.1016/s1074-7613(00)80637-8 · Cited by 321
Self-citation
Cited by
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
“In particular, IKZF3 is critical for plasma cell development, and our data indicate that IKZF3 is essential in multiple myeloma, a plasma cell malignancy, providing a mechanistic basis for therapeutic efficacy in this disorder (18).”
The generation of antibody-secreting plasma cells
Nutt, S. L., Hodgkin, P. D., Tarlinton, D. M., & Corcoran, L. M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3795 · Cited by 1,454
Competence and competition: the challenge of becoming a long-lived plasma cell
Radbruch, A., Muehlinghaus, G., Luger, E. O., Inamine, A., Smith, K. G. C., Dörner, T., & Hiepe, F. (2006) · Nature Reviews Immunology · doi:10.1038/nri1886 · Cited by 1,030
Regulation of plasma-cell development
Shapiro-Shelef, M., & Calame, K. (2005) · Nature Reviews Immunology · doi:10.1038/nri1572 · Cited by 881
Innate Lymphoid Cells: Emerging Insights in Development, Lineage Relationships, and Function
Spits, H., & Cupedo, T. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075053 · Cited by 693
Kumar, V., Ramnarayanan, K., Sundar, R., Padmanabhan, N., Srivastava, S., Koiwa, M., Yasuda, T., Koh, V., Huang, K. K., Tay, S. T., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0683 · Cited by 573
Plasma cells require autophagy for sustainable immunoglobulin production
Pengo, N., Scolari, M., Oliva, L., Milan, E., Mainoldi, F., Raimondi, A., Fagioli, C., Merlini, A., Mariani, E., Pasqualetto, E., et al. (2013) · Nature Immunology · doi:10.1038/ni.2524 · Cited by 425
Nakamura, M., Nishida, N., Kawashima, M., Aiba, Y., Tanaka, A., Yasunami, M., Nakamura, H., Komori, A., Nakamuta, M., Zeniya, M., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.08.010 · Cited by 267
“IKZF3 and IL7R were both replicated and confirmed as PBC susceptibility loci in this study; IKZF3 functions as a transcription factor that participates in the generation of high-affinity bone marrow plasma cells responsible for long-term immunity, and IL7R participates in pre-B cell expansion.(38,39) Collectively, the…”
ResultMultispecific drugs herald a new era of biopharmaceutical innovation
Deshaies, R. J. (2020) · Nature · doi:10.1038/s41586-020-2168-1 · Cited by 262
Blink, E. J., Light, A., Kallies, A., Nutt, S. L., Hodgkin, P. D., & Tarlinton, D. M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042060 · Cited by 260
Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience
Holstein, S. A., & McCarthy, P. L. (2017) · Drugs · doi:10.1007/s40265-017-0689-1 · Cited by 255
The Ikaros gene family: Transcriptional regulators of hematopoiesis and immunity
John, L. B., & Ward, A. C. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.03.006 · Cited by 231
Generation and maintenance of immunological memory
Gourley, T. S., Wherry, E. J., Masopust, D., & Ahmed, R. (2004) · Seminars in Immunology · doi:10.1016/j.smim.2004.08.013 · Cited by 231
Bjorklund, C. C., Lu, L., Kang, J., Hagner, P. R., Havens, C. G., Amatangelo, M., Wang, M., Ren, Y., Couto, S., Breider, M., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.66 · Cited by 221
“15,16,28,29,32 During normal B-cell activation and maturation, the c-Myc/IRF4 regulatory axis is only transiently active during germinal center class switch recombination and in the expansion phase after normal B-cell activation.”
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137
Ikaros fingers on lymphocyte differentiation
Yoshida, T., & Georgopoulos, K. (2014) · International Journal of Hematology · doi:10.1007/s12185-014-1644-5 · Cited by 86
Self-citationThe Ikaros family of zinc-finger proteins
Fan, Y., & Lu, D. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.06.002 · Cited by 61
Genomic landscape of multiple myeloma and its precursor conditions
Alberge, J.-B., Dutta, A. K., Poletti, A., Coorens, T. H. H., Lightbody, E. D., Toenges, R., Loinaz, X., Wallin, S., Dunford, A., Priebe, O., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02196-0 · Cited by 32
The Genetics of Primary Biliary Cholangitis: A GWAS and Post-GWAS Update
Hitomi, Y., & Nakamura, M. (2023) · Genes · doi:10.3390/genes14020405 · Cited by 26
Pourabdollah, M., Bahmanyar, M., Atenafu, E. G., Reece, D., Hou, J., & Chang, H. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0354-2 · Cited by 24
Barankiewicz, J., Szumera-Ciećkiewicz, A., Salomon-Perzyński, A., Wieszczy, P., Malenda, A., Garbicz, F., Prochorec-Sobieszek, M., Misiewicz-Krzemińska, I., Juszczyński, P., & Lech-Marańda, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122683 · Cited by 7
“0001, respectively) confirm their contribution to switch immunoglobulin classes during B-cell maturation [32,33] and verify the reliability of applied assays.”
Background
Metadata
- Authors
- Cortés, M., & Georgopoulos, K.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2004-01-12
- Volume
- 199
- Issue
- 2
- Pages
- 209-219
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2101603234
- Cited by
- 135
- References
- 3
- FWCI
- 1.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.